158 related articles for article (PubMed ID: 36039463)
1. Discontinuation of Immune Checkpoint Inhibitor and Survival in Patients With Non-small-cell Lung Cancer Without a Driver Gene Mutation.
Hattori S; Okauchi S; Sasatani Y; Ohara G; Miyazaki K; Sato S; Kodama T; Shiozawa T; Satoh H; Hizawa N
Anticancer Res; 2022 Sep; 42(9):4589-4595. PubMed ID: 36039463
[TBL] [Abstract][Full Text] [Related]
2. Discontinuation of Immune Checkpoint Inhibitor due to irAEs in NSCLC Patients With EGFR Mutation.
Okauchi S; Miyazaki K; Shiozawa T; Yamada H; Satoh H; Hizawa N
Cancer Diagn Progn; 2023; 3(2):244-250. PubMed ID: 36875301
[TBL] [Abstract][Full Text] [Related]
3. Treatment-free survival after discontinuation of immune checkpoint inhibitors in mNSCLC: a systematic review and meta-analysis.
Hu Y; Liu S; Wang L; Liu Y; Zhang D; Zhao Y
Front Immunol; 2023; 14():1202822. PubMed ID: 37520573
[TBL] [Abstract][Full Text] [Related]
4. Discontinuation due to immune-related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non-small cell lung cancer.
Komiya K; Nakamura T; Abe T; Ogusu S; Nakashima C; Takahashi K; Kimura S; Sueoka-Aragane N
Thorac Cancer; 2019 Sep; 10(9):1798-1804. PubMed ID: 31328416
[TBL] [Abstract][Full Text] [Related]
5. Impact of interstitial lung disease associated with immune checkpoint inhibitors on prognosis in patients with non-small-cell lung cancer.
Yamagata A; Yokoyama T; Fukuda Y; Ishida T
Cancer Chemother Pharmacol; 2021 Feb; 87(2):251-258. PubMed ID: 33394102
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer.
Yamaguchi O; Imai H; Minemura H; Suzuki K; Wasamoto S; Umeda Y; Osaki T; Kasahara N; Uchino J; Sugiyama T; Ishihara S; Ishii H; Naruse I; Mori K; Kotake M; Kanazawa K; Minato K; Kagamu H; Kaira K
Cancer Chemother Pharmacol; 2020 Apr; 85(4):761-771. PubMed ID: 32193618
[TBL] [Abstract][Full Text] [Related]
7. Real-world data on the efficacy and safety of immune-checkpoint inhibitors in elderly patients with non-small cell lung cancer.
Morinaga D; Asahina H; Ito S; Honjo O; Tanaka H; Honda R; Yokouchi H; Nakamura K; Takamura K; Hommura F; Kawai Y; Ito K; Sukoh N; Yokoo K; Morita R; Harada T; Takashina T; Goda T; Dosaka-Akita H; Isobe H;
Cancer Med; 2023 May; 12(10):11525-11541. PubMed ID: 36999734
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.
Mazieres J; Drilon A; Lusque A; Mhanna L; Cortot AB; Mezquita L; Thai AA; Mascaux C; Couraud S; Veillon R; Van den Heuvel M; Neal J; Peled N; Früh M; Ng TL; Gounant V; Popat S; Diebold J; Sabari J; Zhu VW; Rothschild SI; Bironzo P; Martinez-Marti A; Curioni-Fontecedro A; Rosell R; Lattuca-Truc M; Wiesweg M; Besse B; Solomon B; Barlesi F; Schouten RD; Wakelee H; Camidge DR; Zalcman G; Novello S; Ou SI; Milia J; Gautschi O
Ann Oncol; 2019 Aug; 30(8):1321-1328. PubMed ID: 31125062
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of immune checkpoint inhibitor therapy in patients with
Bhandari NR; Hess LM; Han Y; Zhu YE; Sireci AN
Immunotherapy; 2021 Aug; 13(11):893-904. PubMed ID: 34139897
[TBL] [Abstract][Full Text] [Related]
10. Adverse impact of bone metastases on clinical outcomes of patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
Li X; Wang L; Chen S; Zhou F; Zhao J; Zhao W; Su C
Thorac Cancer; 2020 Oct; 11(10):2812-2819. PubMed ID: 32779372
[TBL] [Abstract][Full Text] [Related]
11. Safety and Efficacy of Extended Interval Dosing for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer During the COVID-19 Pandemic.
Hijmering-Kappelle LBM; Hiltermann TJN; Bensch F
Clin Lung Cancer; 2022 Mar; 23(2):143-150. PubMed ID: 35034861
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy-induced pneumonitis in non-small cell lung cancer patients: current concern in treatment with immune-check-point inhibitors.
Sun Z; Wang S; Du H; Shen H; Zhu J; Li Y
Invest New Drugs; 2021 Jun; 39(3):891-898. PubMed ID: 33428078
[TBL] [Abstract][Full Text] [Related]
13. Timing of resumption of immune checkpoint inhibitor therapy after successful control of immune-related adverse events in seven advanced non-small cell lung cancer patients.
Kashiwabara K; Fujii S; Tsumura S; Sakamoto K
Anticancer Drugs; 2020 Sep; 31(8):872-875. PubMed ID: 32796406
[TBL] [Abstract][Full Text] [Related]
14. Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors : Antibiotics immune checkpoint inhibitors in advanced NSCLC.
Schett A; Rothschild SI; Curioni-Fontecedro A; Krähenbühl S; Früh M; Schmid S; Driessen C; Joerger M
Cancer Chemother Pharmacol; 2020 Jan; 85(1):121-131. PubMed ID: 31745593
[TBL] [Abstract][Full Text] [Related]
15. Association Between Pretreatment Chest Imaging and Immune Checkpoint Inhibitor Pneumonitis Among Patients With Lung Cancer.
Wong A; Riley M; Zhao S; Zimmer J; Viveiros M; Wang JG; Esguerra V; Li M; Lopez G; Kendra K; Carbone DP; He K; Alahmadi A; Kaufman J; Memmott RM; Shields PG; Brownstein J; Haglund K; Welliver M; Otterson GA; Presley CJ; Wei L; Owen DH; Ho K
J Natl Compr Canc Netw; 2023 Nov; 21(11):1164-1171.e5. PubMed ID: 37935100
[TBL] [Abstract][Full Text] [Related]
16. Prognostic effect of coexisting TP53 and ZFHX3 mutations in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Zhang L; Zhang T; Shang B; Li Y; Cao Z; Wang H
Scand J Immunol; 2021 Sep; 94(3):e13087. PubMed ID: 35226388
[TBL] [Abstract][Full Text] [Related]
17. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer with
Oya Y; Kuroda H; Nakada T; Takahashi Y; Sakakura N; Hida T
Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32283823
[TBL] [Abstract][Full Text] [Related]
19. Antibiotics impair immune checkpoint inhibitor effectiveness in Hispanic patients with non-small cell lung cancer (AB-CLICaP).
Ruiz-Patiño A; Barrón F; Cardona AF; Corrales L; Mas L; Martín C; Zatarain-Barrón ZL; Recondo G; Ricaurte L; Rojas L; Archila P; Rodríguez J; Sotelo C; Viola L; Vargas C; Carranza H; Otero J; Pino LE; Rolfo C; Rosell R; Arrieta O;
Thorac Cancer; 2020 Sep; 11(9):2552-2560. PubMed ID: 32705787
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer.
Hong L; Aminu M; Li S; Lu X; Petranovic M; Saad MB; Chen P; Qin K; Varghese S; Rinsurongkawong W; Rinsurongkawong V; Spelman A; Elamin YY; Negrao MV; Skoulidis F; Gay CM; Cascone T; Gandhi SJ; Lin SH; Lee PP; Carter BW; Wu CC; Antonoff MB; Sepesi B; Lewis J; Gibbons DL; Vaporciyan AA; Le X; Jack Lee J; Roy-Chowdhuri S; Routbort MJ; Gainor JF; Heymach JV; Lou Y; Wu J; Zhang J; Vokes NI
Nat Commun; 2023 Feb; 14(1):695. PubMed ID: 36755027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
